Phase III Trial of Sirolimus in IBM

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The hypothesis is that Sirolimus, (Rapamycin (R)) which is currently used in organ transplantation and works by blocking the activity of T effector cells but preserving T regulatory cells, as well as by inducing autophagy (protein degradation), will be effective in IBM to slow or stabilize disease progression, helping to maintain patient function and independence. This phase III trial will confirm pilot data showing statistically significant clinical outcomes.
Epistemonikos ID: a1963834bef5a8d7e6f8493db9c7a4663b7563a3
First added on: May 08, 2024